Research advances on lipoprotein(a) in cerebrovascular diseases

doi:10.3969/j.issn.1006-7795.2025.01.012

Abstract

Abstract: Lipoprotein(a)［Lp(a)］ is a unique plasma lipoprotein particle with a distinct structure that has garnered significant research attention due to its strong association with various cerebrovascular diseases. Recent studies underscore elevated Lp(a) levels as a critical risk factor, with multiple Lp(a)-targeted therapies advancing through clinical trials. This review explores the structural, functional, and genetic features of Lp(a), its connection to cerebrovascular diseases, and the latest therapeutic strategies aimed at reducing its impact. By consolidating these advancements, we aim to provide new insights for Lp(a)-centered research and propose innovative approaches for cerebrovascular disease prevention and management.

Key words: lipoprotein(a), cerebrovascular diseases, RNA-targeted therapies, advances in clinical studies

CLC Number:

R743

Guo Yibing, Meng Ran. Research advances on lipoprotein(a) in cerebrovascular diseases[J]. Journal of Capital Medical University, 2025, 46(1): 71-75.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2025.01.012

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2025/V46/I1/71

References

［1］ Arnold M, Schweizer J, Nakas C T, et al. Lipoprotein(a)is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study［J］. Eur Heart J, 2021, 42(22): 2186－2196.
［2］ Berg K. A new serum type system in man-the LP system［J］. Acta Pathol Microbiol Scand, 1963, 59: 369－382.
［3］ Konrad S, Asma N , Florian K , Gerd U, et al. Structure, function, and genetics of lipoprotein (a)［J］. J Lipid Res, 2016, 57(8):1339-1359.
［4］ Clarke R, Peden J F, Hopewell J C, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease［J］. N Engl J Med, 2009, 361(26): 2518－2528.
［5］ Kim B J, Lee M Y, Choi H I, et al. Lipoprotein(a)-related cardiovascular and all-cause mortalities in Korean adults［J］. Eur J Prev Cardiol, 2023, 30(4): 308－317.
［6］ Lin L J, Deng K Q, Chen Z, et al. Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population［J］. Atherosclerosis, 2023, 372: 1－9.
［7］ Guan W H, Cao J, Steffen B T, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis［J］. Arterioscler Thromb Vasc Biol, 2015, 35(4): 996－1001.
［8］ Kiechl S, Willeit J. The mysteries of lipoprotein(a)and cardiovascular disease revisited［J］. J Am Coll Cardiol, 2010, 55(19): 2168－2170.
［9］ Labudovic D, Kostovska I, Tosheska T K, et al. Lipoprotein(a)-link between atherogenesis and thrombosis［J］. Prague Med Rep, 2019, 120(2/3): 39－51.
［10］ Etingin O R, Hajjar D P, Hajjar K A, et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis［J］. J Biol Chem, 1991, 266(4):2459-2465.
［11］ Pan S, Kleppe L S, Witt T A, et al. The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis［J］. Thromb Haemost, 2004, 92(3): 495－502.
［12］ van der Valk F M, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans［J］. Circulation, 2016, 134(8): 611－624.
［13］ Tsimikas S, Witztum J L. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity［J］. Curr Opin Lipidol, 2008, 19(4): 369－377.
［14］ Stefanadis C, Antoniou C K, Tsiachris D, et al. Coronary atherosclerotic vulnerable plaque: current perspectives［J］. J Am Heart Assoc, 2017, 6(3): e005543.
［15］ Duan Y, Zhao D, Sun J, et al. Lipoprotein(a) is associated with the progression and vulnerability of new-onset carotid atherosclerotic plaque［J］. Stroke, 2023, 54(5): 1312－1319.
［16］ van Dam-Nolen D H K, van Dijk A C, Crombag G A J C, et al. Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: the Plaque at RISK (PARISK) study［J］. Atherosclerosis, 2021, 329: 22－29.
［17］ Xia S, Qiu W D, Cai A P, et al. The association of lipoprotein(a) and intraplaque neovascularization in patients with carotid stenosis: a retrospective study［J］. BMC Cardiovasc Disord, 2021, 21(1): 285.
［18］ Feigin V L, Brainin M, Norrving B, et al. World Stroke Organization (WSO): global stroke fact sheet 2022［J］. Int J Stroke, 2022, 17(1): 18－29.
［19］ Langsted A, Nordestgaard B G, Lipoprotein K P . Elevated lipoprotein(a) and risk of ischemic stroke［J］. J Am Coll Cardiol, 2019, 74(1): 54－66.
［20］ Pan Y S, Li H, Wang Y L, et al. Causal effect of Lp(a)［lipoprotein(a)］ level on ischemic stroke and alzheimer disease: a mendelian randomization study［J］. Stroke, 2019, 50(12): 3532－3539.
［21］ Arora P, Kalra R, Callas P W, et al. Lipoprotein(a) and risk of ischemic stroke in the REGARDS study［J］. Arterioscler Thromb Vasc Biol, 2019, 39(4): 810－818.
［22］ Lackova A, Gdovinova Z, Kozarova M, et al. Lipoprotein (a) concentration as a risk factor for ischaemic stroke and its subtypes［J］. Neurol Neurochir Pol, 2024, 58(3): 316－322.
［23］ Rudin S, Kriemler L, Dittrich T D, et al. Lipoprotein(a) as a blood marker for large artery atherosclerosis stroke etiology: validation in a prospective cohort from a Swiss stroke center［J］. Swiss Med Wkly, 2024, 154: 3633.
［24］ Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated lipoprotein(a) and risk of atrial fibrillation: an observational and mendelian randomization study［J］. J Am Coll Cardiol, 2022, 79(16): 1579－1590.
［25］ Guo J C, Zhou Y, Zhou B F. Development and validation of a new nomogram model for predicting acute Ischemic stroke in elderly patients with non-valvular atrial fibrillation: a single-center cross-sectional study［J］. Clin Interv Aging, 2024, 19:67-79.
［26］ Feng Z, Xu J, Jin A, et al. Elevated homocysteine intensify the effect of lipoprotein(a)on stroke recurrence［J］. J Am Heart Assoc, 2023, 12(1): e026707.
［27］ Xu J, Hao X W, Zhan R, et al. Effect of lipoprotein(a) on stroke recurrence attenuates at low LDL-C (low-density lipoprotein) and inflammation levels［J］. Stroke, 2022, 53(8): 2504－2511.
［28］ Dong W, Zhong X, Yuan K, et al. Lipoprotein(a)and functional outcome of acute ischemic stroke when discordant with low density lipoprotein-cholesterol［J］. Postgrad Med J, 2023, 99(1177): 1160－1166.
［29］ Skuza A A, Polak M, Undas A. Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties［J］. J Thromb Thrombolysis, 2019, 47(1): 8－15.
［30］ Kronenberg F, Mora S, Stroes E S G, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement［J］. Eur Heart J, 2022, 43(39): 3925－3946.
［31］ Pearson G J, Thanassoulis G, Anderson T J, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults［J］. Can J Cardiol, 2021, 37(8): 1129－1150.
［32］ Safarova M S, Moriarty P M. Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein(a)［J］. Curr Atheroscler Rep, 2023, 25(7):391-404.
［33］ Sahebkar A, Reiner Ž, Simental-Mendía L E, et al. Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials［J］. Metabolism, 2016, 65(11): 1664－1678.
［34］ Sahebkar A, Serban M C, Penson P, et al. The effects of tamoxifen on plasma lipoprotein(a) concentrations: systematic review and Meta-analysis［J］. Drugs, 2017, 77(11): 1187－1197.
［35］ Alkhalil M. Lipoprotein(a) reduction in persons with cardiovascular disease［J］. N Engl J Med, 2020, 382(21): e65.
［36］ O'Donoghue M L, Rosenson R S, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a)in cardiovascular disease［J］. N Engl J Med, 2022, 387(20): 1855－1864.
［37］ Diaz N, Perez C, Escribano A M, et al. Discovery of potent small-molecule inhibitors of lipoprotein(a)formation［J］. Nature, 2024, 629(8013): 945－950.
［38］ Nicholls S J, Nissen S E, Fleming C, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial［J］. JAMA, 2023, 330(11): 1042－1053.
［39］ Gaudet D, Watts G F, Robinson J G, et al. Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the phase 3 ODYSSEY program)［J］. Am J Cardiol, 2017, 119(1): 40－46.
［40］ Watts G F, Chan D C, Somaratne R, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics［J］. Eur Heart J, 2018, 39(27): 2577－2585.
［41］ O'Donoghue M L, Fazio S, Giugliano R P, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk［J］. Circulation, 2019, 139(12): 1483－1492.
［42］ Curry W T J, Butler W E, Barker F G 2. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988－2002［J］. Neurosurgery, 2005, 57(1): 97－108; discussion 97－108.